Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense

Merck came out ahead in the immuno-oncology combination showdown at AACR, with a strong overall survival benefit for Keytruda/chemo in the Phase III KEYNOTE-189 study in first-line NSCLC. The data were seen as practice-changing, but Bristol's CheckMate-227 trial of Opdivo/Yervoy failed to impress in the same way.

Instagram style filter silhouette of a successful woman or girl arms raised celebrating at sunrise or sunset in front of the New York City Skyline

Merck & Co. Inc.'s PD-1 inhibitor Keytruda has emerged as the clear winner in non-squamous non-small cell lung cancer (NSCLC), with consistent and striking survival data for the combination of the drug with chemotherapy in the Phase III KEYNOTE-189 study, leaving an uncertain future for Bristol-Myers Squibb Co.'s competing Opdivo/Yervoy combination.

On April 16, the American Association for Cancer Research (AACR) meeting featured full data from landmark studies in first-line metastatic...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer